The FDA approved Eli Lily drug Mounjaro as a treatment for type 2 diabetes. The decision gives the pharmaceutical giant a new competitor to a blockbuster drug from rival Novo Nordisk, as well as a successor to its blockbuster diabetes drug Trulicity.